SSX1 and synovial sarcoma: To extend our findings beyond the cell lines, we analyzed patient-derived synovial sarcoma cells (namely, SS18-SSX1-positive NCC-SS1 (Kito et al., 2018) and SS18-SSX2-positive NCC-SS2 (Oyama et al., 2018)) for FK228-PP2 combination treatment.